Powering Advancements
in Heart Health

The ability to detect cardiac biomarkers at ultra-low levels is advancing the future of heart health.

Simoa assays have the potential to detect cardiac biomarkers, which are instrumental for predicting major adverse cardiovascular events, development of heart failure or transition to end-stage kidney disease, earlier than ever before. Further, the ability to detect minute changes in these biomarkers could enable the identification of at-risk patients earlier in their disease progression to guide more personalized, preventive care. 

Cardiology Assays
Available for Scientific Research

Latest Publications

Quanterix' digital health solution, Simoa, is changing the way researchers, academics and drug manufacturers measure and predict adverse cardiovascular events. Quanterix' focus in cardiology is growing with a network of academic researchers and pharmaceutical and biotech partners. Learn about Simoa's application in cardiology by exploring our scientific publications and journals.

Latest News

Relations between elevated circulating cardiac troponin I (cTnI) levels and adverse cardiac outcomes were established prior to the advent of methods to measure extremely low levels of cTnI. Recently developed ELISA assays/platforms with ultra-high sensitivity cTnI (u-hs-cTnI) allow accurate…
Despite aggressive intervention, patients who survive an out-of-hospital cardiac arrest (OHCA) generally have very poor prognoses, with nationwide survival rates of approximately 10–20%.